{"filing":{"accession_number":"0001493152-26-042672","cik":"0000109657","ticker":"GTBP","company_name":"GT Biopharma, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-14","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226042672/form8-k.htm"},"events":[{"id":33520,"run_id":30822,"accession_number":"0001493152-26-042672","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"GT Biopharma entered into a Securities Purchase Agreement on September 14, 2026, to issue up to 8,277.778 shares of Series M 10% Convertible Preferred Stock (with aggregate stated value of $8,277,778 for $7,450,000) plus warrants to purchase common stock equal to 100% of conversion shares, with additional Greenshoe Rights for up to $30,000,000 more. The preferred stock is convertible into common stock at $6.10 per share, and the warrants are exercisable immediately. This is a classic dilutive private placement of convertible securities and warrants, disclosed under Items 1.01 and 3.02, designed to raise capital while creating substantial dilution to existing shareholders through conversion and warrant exercise rights.","company_name":"GT Biopharma, Inc.","ticker":"GTBP","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":36981,"accession_number":"0001493152-26-042672","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"GT Biopharma entered into a Securities Purchase Agreement on September 14, 2026, to issue up to 8,277.778 shares of Series M 10% Convertible Preferred Stock (with aggregate stated value of $8,277,778 for $7,450,000) plus warrants to purchase common stock equal to 100% of conversion shares, with additional Greenshoe Rights for up to $30,000,000 more. The preferred stock is convertible into common stock at $6.10 per share, and the warrants are exercisable immediately. This is a classic dilutive private placement of convertible securities and warrants, disclosed under Items 1.01 and 3.02, designed to raise capital while creating substantial dilution to existing shareholders through conversion and warrant exercise rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:58:37.669271+00:00","company_name":"GT Biopharma, Inc.","ticker":"GTBP","filing_date":"2026-09-15"}]}